BIO-TECHNE CORP shareholders Q2 2022

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q2 2022
NameSharesValueWeighting ↓
PICTON MAHONEY ASSET MANAGEMENT 540$187,0000.01%
BANK OF AMERICA CORP /DE/ 186,756$64,737,0000.01%
STIFEL FINANCIAL CORP 12,085$4,189,0000.01%
Bridgewater Associates 4,681$1,623,0000.01%
CIBC Asset Management Inc 4,747$1,646,0000.01%
MERCER GLOBAL ADVISORS INC /ADV 2,897$1,004,0000.01%
ROCKY MOUNTAIN ADVISERS, LLC 13$5,0000.01%
Livforsakringsbolaget Skandia, Omsesidigt 200$69,0000.01%
ONTARIO TEACHERS PENSION PLAN BOARD 1,280$444,0000.01%
BARCLAYS PLC 28,566$9,901,0000.01%
PineBridge Investments, L.P. 1,265$438,0000.01%
OSAIC HOLDINGS, INC. 7,569$2,626,0000.01%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 12,662$4,389,0000.01%
J.P. Morgan Private Wealth Advisors LLC 7,078$2,454,0000.01%
GOLDMAN SACHS GROUP INC 58,003$20,105,0000.01%
Bell Investment Advisors, Inc 45$16,0000.01%
Fieldpoint Private Securities, LLC 45$16,0000.01%
Gs Investments, Inc. 20$8,0000.01%
Tradition Wealth Management, LLC 106$37,0000.01%
COMMONWEALTH EQUITY SERVICES, LLC 5,937$2,058,0000.01%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q2 2022. To view BIO-TECHNE CORP's shareholder history, click here.